The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multipler games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *. In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923
PMID: 22209829

Your name *
First Last
Brittany Mosser

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada
University of Seattle, Seattle, USA

Your e-mail address *
abc@gmail.com
bmosser@uw.edu
Title of your manuscript *
Provide the (draft) title of your manuscript.

Effectiveness of Mental Health Apps for Distress during COVID-19 in U.S. Unemployed and Essential Workers: A Remote Pragmatic Clinical Trial

Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

7 Cups of Tea, Beautiful Mood, Calm, COVID C:

Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Not applicable to the present study

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App
e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer
URL of an image/screenshot (optional)

Your answer

Accessibility *
Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Mental Health Distress

Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

PHQ, GAD, DERS, SBQ-R
Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

Your answer

Recommended "Dose" *
What do the instructions for users say on how often the app should be used?

- [ ] Approximately Daily
- [ ] Approximately Weekly
- [ ] Approximately Monthly
- [ ] Approximately Yearly
- [ ] "as needed"
- [ ] Other: Varies by app
Approx. Percentage of Users (starters) still using the app as recommended after 3 months

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other:
Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- [ ] not submitted yet - in early draft status
- [x] not submitted yet - in late draft status, just before submission
- [ ] submitted to a journal but not reviewed yet
- [ ] submitted to a journal and after receiving initial reviewer comments
- [ ] submitted to a journal and accepted, but not published yet
- [ ] published
- [ ] Other:

Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- [ ] not submitted yet / unclear where I will submit this
- [ ] Journal of Medical Internet Research (JMIR)
- [x] JMIR mHealth and UHealth
- [ ] JMIR Serious Games
- [ ] JMIR Mental Health
- [ ] JMIR Public Health
- [ ] JMIR Formative Research
- [ ] Other JMIR sister journal
- [ ] Other:
Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Other:

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- yes
- Other:
1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use “web-based” and/or “mobile” and/or “electronic game” in the title. Avoid ambiguous terms like “online”, “virtual”, “interactive”. Use “Internet-based” only if Intervention includes non-web-based Internet components (e.g. email), use “computer-based” or “electronic” only if offline products are used. Use “virtual” only in the context of “virtual reality” (3-D worlds). Use “online” only in the context of “online support groups”. Complement or substitute product names with broader terms for the class of products (such as “mobile” or “smart phone” instead of “iphone”), especially if the application runs on different platforms.

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All interventions considered in this study were mental health apps, which is included in the title.

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., “with telephone support”).
Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our trial was only concerned with mental health apps so no non-web-based components were included.

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5
subitem not at all important 〇 〇 〇 〇 〇 essential

Does your paper address subitem 1a-iii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study evaluated effectiveness of mental health apps for distress during COVID-19 in U.S. unemployed and essential Workers, which is described in the title.

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

This study evaluated effectiveness of mental health apps for distress during COVID-19 in U.S. unemployed and essential Workers, which is described in the title.
1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important       essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The following sentence is included in the abstract: "Participants were randomized to one of four free commercial mobile applications for managing distress that were (1) highly rated by PsyberGuide and (2) met criteria for intervention features these participants indicated were desirable in a previous survey."

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important       essential
Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

A description of the level of human involvement does not seem necessary for this study and has not been included in the abstract.

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

The is described throughout the paper including "Participants used the apps for 4 weeks and completed baseline and 4-weeks self-assessments of depression, anxiety emotional regulation and suicide risk."
1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This information is provided in the results section and included CONSORT diagram including "There were 3486 individuals assessed for eligibility, 1569 were excluded for not meeting good-actor criteria (n= 988) or not meeting RCT inclusion criteria (n=581). A total of 1,717 individuals were randomized to Beautiful Mood (n=425), COVID Coach (n=431), Calm (n=424), or 7 Cups of Tea (n=437). Among those allocated to a condition, 838 participants completed the RCT baseline assessment while 643 participants completed the follow-up assessment. 581 individuals reported using the assigned app and 62 reported using a non-assigned app." Usage is also specifically reported throughout the paper including Table 2. Clinical outcomes are discussed starting on page 15 and in Table 3.
1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials
Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 1b-v?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our study is not a negative trial but we do state the following: "We also cannot rule out regression to the mean, as people who used the attention control app had outcomes similar to participants who used the active apps."

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale
2a-i) Problem and the type of system/solution
Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in “Methods” under 5)

1  2  3  4  5

subitem not at all important  ○  ○  ○  ○  ○  essential

Does your paper address subitem 2a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is discussed throughout the paper, including "Access to mental health care by essential workers and the people unemployed due to COVID-19 related business closures and social distancing policies has been challenging [1–3]. To address this problem, health care organizations have created free mobile applications for stress related to COVID-19...There is limited information on the effectiveness of mental health apps, particularly free, self-guided commercial apps."

2a-ii) Scientific background, rationale: What is known about the (type of) system
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1  2  3  4  5

subitem not at all important  ○  ○  ○  ○  ○  essential
Consort-Ehealth (V 1.6.1) - Submission/Publication Form

Does your paper address subitem 2a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Research on self-guided apps is mixed with some studies finding them to be minimally effective [6–8], and others reporting beneficial effects; we note here that most evidence points to the superiority of coach-based apps for depression and anxiety outcomes, but effect sizes for self-guided apps are still notable [9], and offer an opportunity for stress management in populations who do not have the financial or time resources to avail themselves of coaching services [10]. ... Still, evidence for free, commercial apps is limited and calls for additional research [14,15], particularly in the context of COVID-19 [16] have been made."

2b) In introduction: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The main objectives of this study were
1. Determine if users of these apps show significant improvement on anxiety, depression, emotion regulation, and suicide risk.
2. Identify differences among the apps in use, usability, and acceptability.
3. Determine if there is a dose-response relationship such that frequency of app use is positively associated with improvement on depression, anxiety, emotional regulation, and suicide risk.
4. Identify outcome differences among apps in this dose-response relationship."

Methods

https://docs.google.com/forms/d/e/1FAIpQLSfZBwOc_OimqcS64RdfIFqvrTSkZQL2-3O809hrL5Sw/viewform?hl=en_US&formkey=dGlKd2
3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This remote pragmatic clinical trial used simple randomization with parallel assignment comparing 3 active apps to an attention control app."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No important changes to methods occurred after trial commencement.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other “unexpected events” that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].
4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Inclusion criteria included: ≥19 years old, living in the United States, English-speaking, access to a mobile device, agreement to be contacted after the initial survey, and report of depression (PHQ-2 [≥3]) [25], anxiety (GAD-2 [≥3]) [26], risk for suicidal behaviors (SBQ-R [≥7]) [27] or history of past suicide attempt [28]."

4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | ○ | ○ | ○ | ○ | ○ | essential |
Does your paper address subitem 4a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were recruited nationally via Prolific, an online research platform which includes several safeguards to preserve data quality[20–22], to minimize bad actors and has shown to be reliable, efficient, and affordable for remote data collection for behavioral research [23]."

---

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

---

Does your paper address subitem 4a-ii? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is addressed throughout the paper, including "Participants were recruited nationally via Prolific, an online research platform...." and "After volunteering on Prolific and providing consent, participants completed all measures in a web-based REDCap interface."
4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"In the consent, participants were explained the purpose of the study, that that would be randomized to one of four mobile apps, and would be asked to complete surveys before treatment began and four weeks later. Participants were also told how data were stored and managed and approximately how long each survey would take."

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

All data were collected online from English-speaking individuals living in the US.
4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

1  2  3  4  5

subitem not at all important   ○  ○  ○  ○  ○   essential

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were randomized after completing a web-based baseline assessment of mood and paid $1 (see measures). Participants were asked to use the app as instructed by the developers and then completed a web-based post-treatment survey at four weeks."

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item – describe only if this may bias results)

1  2  3  4  5

subitem not at all important   ○  ○  ○  ○  ○   essential
Does your paper address subitem 4b-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

We do not believe this would bias results and have not discussed this in the paper. Institutional affiliation was shared on the consent form and on each screen of the web-based assessments.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).

Does your paper address subitem 5-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No developers or sponsors of the apps examined were involved in the study.
5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5
subitem not at all important  ○  ○  ○  ○  ○  essential

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No authors were involved in the development of the apps or any formative evaluations evaluated in this study.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was “frozen” during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

1 2 3 4 5
subitem not at all important  ○  ○  ○  ○  ○  essential
Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No authors were or are involved with the apps and have no history or specific knowledge of revisions or updates to those platforms.

---

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential                   |   |   |   |   |   |

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We selected apps based on the following criteria: (1) they were free, (2) reflected desired app features during COVID-19 as identified in the survey study [4], and (3) had good ratings on PsyberGuide [4]."

"A dichotomized fidelity measure was created in accordance with each app’s recommended use found on their websites. Daily use was recommended for apps Beautiful Mood [47], COVID Coach [48], and Calm [49], while weekly use was recommended for 7 Cups of Tea [50]."
5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used.

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No authors were or are involved with the apps and have no history or specific knowledge of source code, algorithms, etc of the apps involved.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.
Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

COVID Coach: https://mobile.va.gov/app/covid-coach
Beautiful Mood: https://www.beautifulmood.app/
Calm: https://www.calm.com/
7 Cups of Tea: https://www.7cups.com/

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

“We selected apps based on the following criteria: (1) they were free...”
“Participants received their app assignment through a URL to the Google Play store or Apple App Store.”
5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], "whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No authors were involved in the design of the apps evaluated.

"We selected apps based on the following criteria: (1) they were free, (2) reflected desired app features during COVID-19 as identified in the survey study [4], and (3) had good ratings on PsyberGuide [4]. The three active app interventions included 1) meditation (Calm), 2) COVID-19 Coping (COVID Coach), and 3) chat and positive psychology (7 Cups of Tea). The attention control app used only mood tracking (Beautiful Mood) and did not include any intervention elements the other apps possessed (mindfulness meditation, emotional coping skills, social connection or positive psychology approaches)."
5-ix) Describe use parameters

Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"A dichotomized fidelity measure was created in accordance with each app’s recommended use found on their websites. Daily use was recommended for apps Beautiful Mood [47], COVID Coach [48], and Calm [49], while weekly use was recommended for 7 Cups of Tea [50]."

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem 5-x?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study evaluated self-guided apps and all assessments were completed via automated web-based forms.

5-xi) Report any prompts/reminders used
Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

subitem not at all important

1 2 3 4 5 essential

Does your paper address subitem 5-xi? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study team did not prompt participants to use their assigned app. Participants received a prompt to complete the post-app use assessment via Prolific.
5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

subitem not at all important 1 2 3 4 5 essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

This is not applicable to this study as this study evaluated self-guided mental health interventions.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Primary Clinical Outcomes. Participants completed measures of depression (PHQ-9) [25,42,43], anxiety (GAD-7) [26,44,45], and difficulties with emotion dysregulation (Difficulties in Emotion Regulation – Short Form [DERS-SF]) [46], and suicidal behaviors (SBQ-R) [27] at baseline and follow-up.

App Use. As we were not able to collect in-app use data, participants were asked how often they used the app that they were assigned to over the past 4 weeks on a scale of 1 Never Downloaded the App to 8 Multiple Times per Day. ...

Fidelity. A dichotomized fidelity measure was created in accordance with each app’s recommended use found on their websites. Daily use was recommended for apps Beautiful Mood [47], COVID Coach [48], and Calm [49], while weekly use was recommended for 7 Cups of Tea [50].

Usability. App usability was assessed with the Intervention Usability Scale (IUS) [51], a 10-item measure that assesses intervention usability through its likeability, learnability, difficulty, need for support, system integration, and efficiency. ...

Acceptability and Appropriateness. The degree to which the app was satisfactory and appropriate (i.e., the fit and relevance of the intervention), was measured with the Acceptability Intervention Measure (AIM) and Intervention Appropriateness Measure (IAM) [53]."

"Participants were randomized after completing a web-based baseline assessment of mood and paid $1 (see measures). Participants were asked to use the app as instructed by the developers and then completed a web-based post-treatment survey at four weeks."
Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

CHERRIES criteria is addressed throughout the paper. For example, “The survey was developed by the study lead investigators (PAA and KAM), measures were selected for their validity and reliability, and where there were measures that had been validated for on-line use, we selected those measures.” AND “The PHQ9 and GAD-7 have been used successfully as on-line survey instruments and have been validated as on-line instruments [47,48].”

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

"App Use. As we were not able to collect in-app use data, participants were asked how often they used the app that they were assigned to over the past 4 weeks on a scale of 1 Never Downloaded the App to 8 Multiple Times per Day. To ease interpretation, results presented here are for response options collapsed into four categories, with findings highly similar in both categorization schemes."

"Fidelity. A dichotomized fidelity measure was created in accordance with each app’s recommended use found on their websites. Daily use was recommended for apps Beautiful Mood [47], COVID Coach [48], and Calm [49], while weekly use was recommended for 7 Cups of Tea [50]."
6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | |
| essential | | | | |

Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

Qualitative feedback was not obtained from participants.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no changes to trial outcomes after the trial commenced.

7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed
7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

1 2 3 4 5

subitem not at all important    ○    ○    ○    ○    ○    essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A priori power analysis for an ANOVA F test indicated that a sample size of 800 (n=200 participants in each of the active and control app conditions) would be sufficient with a power of .80 and an alpha of .05 for a minimum detectable effect size (MDES) of Cohen’s d=.24 for main effect comparisons between any two conditions. The post-hoc power analysis for 643 participants with complete data found an MDES of Cohen's d=.29 for main effect comparisons between any two conditions. Previous research has found an average Hedges g effect size (a comparable effect size to Cohen's d but corrected for small samples) on self-guided mental health apps to be 0.50, and for self-guided tools to be .24 [54]."

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to this study.
8a) Method used to generate the random allocation sequence
NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were randomized by study staff using random allocation functions in Excel and received their app assignment through a URL to the Google Play store or Apple App Store."

8b) Type of randomization; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A total of 1,717 individuals were randomized to Beautiful Mood (n=425), COVID Coach (n=431), Calm (n=424), or 7 Cups of Tea (n=437). Among those allocated to a condition, 838 participants completed the RCT baseline assessment while 643 participants completed the follow-up assessment. 581 individuals reported using the assigned app and 62 reported using a non-assigned app. For this intention to treat trial, all randomized participants were included in the primary analysis."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were randomized by study staff using random allocation functions in Excel and received their app assignment through a URL to the Google Play store or Apple App Store."  
"A total of 1,717 individuals were randomized to Beautiful Mood (n=425), COVID Coach (n=431), Calm (n=424), or 7 Cups of Tea (n=437)."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were randomized by study staff using random allocation functions in Excel and received their app assignment through a URL to the Google Play store or Apple App Store."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment
11a-i) Specify who was blinded, and who wasn’t

Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were blinded to the study hypotheses but not condition."
"Participants were randomized by study staff using random allocation functions in Excel and received their app assignment through a URL to the Google Play store or Apple App Store."

11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem 11a-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In the consent, participants were explained the purpose of the study, that that would be randomized to one of four mobile apps..."

11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The three active app interventions included 1) meditation (Calm), 2) COVID-19 Coping (COVID Coach), and 3) chat and positive psychology (7 Cups of Tea). The attention control app used only mood tracking (Beautiful Mood) and did not include any intervention elements the other apps possessed (mindfulness meditation, emotional coping skills, social connection or positive psychology approaches)."

12a) Statistical methods used to compare groups for primary and secondary outcomes
NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed
Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"T-tests and crosstabulations with chi-square tests compared demographic and baseline clinical outcomes by missing data status at follow-up timepoint. Chi-square tests examined the association between condition assignment and compliance (whether a participant used the app they were assigned to or used an alternative app). All analyses were intent-to-treat. Analyses of variance were used to compare conditions on AIM, IAM, and IUS scores at follow-up, with Tukey Honestly Significant Difference (HSD) tests making pairwise post-hoc comparisons among all apps. Mixed effects models using restricted maximum likelihood estimation were built to test linear time change on the PHQ-9, GAD-7, SBQ-R, and DERS-SF, and to test for condition differences at follow-up and change slope. We applied mixed effects models with two timepoints nested within person. ... To test whether there was a dose-response relationship such that the app use frequency was associated with rate of change on PHQ-9, GAD-7, SBQ-R, and DERS-SF scores, we computed another series of mixed effects models for each outcome. An initial model included variables for time and frequency of use, a second model added condition terms for each app using Beautiful Mood as reference, a third model added condition x frequency interaction terms for each app, and the fourth model included time, frequency, and a time x frequency interaction term. Model comparisons applied -2 Log Likelihood, Akaike Information Criterion, and Bayesian Information deviance statistics. To test the impact of app use frequency on change over time, similar nested model testing was applied using an initial null model, followed by models that added dosage, dosage x time interaction, and condition assignment. "

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

1 2 3 4 5
subitem not at all important  ○  ○  ○  ○  ○  essential
Does your paper address subitem 12a-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"T-tests and crosstabulations with chi-square tests compared demographic and baseline clinical outcomes by missing data status at follow-up timepoint."
"A total of 643/838 (76.7%) provided a follow-up assessment. There were no significant differences between those missing or not missing follow-up assessments on demographic data in Table 1 or clinical measures at baseline."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no subgroup analyses or adjusted analyses.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study received ethics approval from the University of Washington Institutional Review Board (STUDY00010842)."

---

x26-ii) Outline informed consent procedures
Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1  2  3  4  5
subitem not at all important  ○  ○  ○  ○  ○  essential

Does your paper address subitem X26-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants completed electronic informed consent prior to study completion. "The study received ethics approval from the University of Washington Institutional Review Board (STUDY00010842). In the consent, participants were explained the purpose of the study, that that would be randomized to one of four mobile apps, and would be asked to complete surveys before treatment began and four weeks later. Participants were also told how data were stored and managed and approximately how long each survey would take."
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

"Participants were offered crisis management resources when they endorsed the 9th item of the PHQ-9 or were over the cut-off for the SBQ-R."
Does your paper address CONSORT subitem 13a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"There were 3486 individuals assessed for eligibility, 1569 were excluded for not meeting good-actor criteria (n= 988) or not meeting RCT inclusion criteria (n=581). A total of 1,717 individuals were randomized to Beautiful Mood (n=425), COVID Coach (n=431), Calm (n=424), or 7 Cups of Tea (n=437). Among those allocated to a condition, 838 participants completed the RCT baseline assessment while 643 participants completed the follow-up assessment. 581 individuals reported using the assigned app and 62 reported using a non-assigned app. For this intention to treat trial, all randomized participants were included in the primary analysis."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram)
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Among those allocated to a condition, 838 participants completed the RCT baseline assessment while 643 participants completed the follow-up assessment. 581 individuals reported using the assigned app and 62 reported using a non-assigned app."
13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Figure 1 presents the Consolidated Standards of Reporting Trails (CONSORT) diagram."

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were recruited from October through December 2020"
14a-i) Indicate if critical “secular events” fell into the study period

Indicate if critical “secular events” fell into the study period, e.g., significant changes in Internet resources available or “changes in computer hardware or Internet delivery resources”

1  2  3  4  5

subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 14a-i? 

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No critical secular events specifically related to availability of internet resources occurred during the study. Secular events pertaining to COVID-19 are described.

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to this study.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
Table 1 presents individual-level demographic data.

**15-i) Report demographics associated with digital divide issues**

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | ⬜ | ⬜ | ⬜ | ⬜ | ⬜ |
| essential |   |   |   |   |   |

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Table 1 presents individual-level demographic data. The analytic sample consisted of 838 adults with a mean (SD) age of 31.1 (9.5) years. Most patients identified as women (467/833, 56.1%) and White (616/838, 73.5%). There were no significant differences in demographics by condition."

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
16-i) Report multiple “denominators” and provide definitions

Report multiple “denominators” and provide definitions: Report N's (and effect sizes) “across a range of study participation [and use] thresholds” [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants “used” the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define “use” of the intervention.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

“There were 3486 individuals assessed for eligibility, 1569 were excluded for not meeting good-actor criteria (n= 988) or not meeting RCT inclusion criteria (n=581). A total of 1,717 individuals were randomized to Beautiful Mood (n=425), COVID Coach (n=431), Calm (n=424), or 7 Cups of Tea (n=437). Among those allocated to a condition, 838 participants completed the RCT baseline assessment while 643 participants completed the follow-up assessment. 581 individuals reported using the assigned app and 62 reported using a non-assigned app. For this intention to treat trial, all randomized participants were included in the primary analysis.”

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

An ANOVA found a significant difference on the IUS among the conditions (mean(Beautiful Mood) 72.9, SD 16.7; mean(Covid Coach) 71.2, SD 15.4; mean(Calm) 66.8, SD 17.3; mean(7 Cups) 65.2, SD 17.7). Tukey HSD post hoc tests indicated Beautiful Mood was significantly more usable than Calm (mean difference = 6.0, 95% CI 1.2-10.8; P = .007) and 7 Cups of Tea (mean difference = 7.7, 95% CI 2.9-2.5; P < .001). COVID Coach was significantly more usable than 7 Cups of Tea (mean difference = 6.1, 95% CI 1.2-10.9; P = .007). We found no significant differences on app acceptability (overall AIM mean = 3.5, SD = 1.0, 95% CI 3.4-3.6; P = .22) or appropriateness (overall IAM mean = 3.6, SD = 0.9, 95% CI 3.6-3.7; P = .48).

Table 3 displays the reporting sample size, mean scores, and standard deviation at each timepoint for the PHQ-9, GAD-7, SBQ-R, and DERS-SF for each app...From baseline to follow-up, participants improved an estimated -1.5 points on the PHQ-9 (SE 0.2; 95% CI -1.1--1.8; P < .001) and -1.3 points on the GAD-7 (SE 0.2; 95% CI -1.0--1.6; P < .001).
17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as “average session length”. These must be accompanied by a technical description how a metric like a “session” is defined (e.g., timeout after idle time) [1] (report under item 6a).

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"App use
A crosstabulation with chi-square test found significant differences among the apps in the amount of use participants reported; participants used Beautiful Mood more frequently and Covid Coach and 7 Cups of Tea less frequently (see Table 2)."

"Dosage
Mixed effects models were computed to examine the relation of frequency of app use with change over time on the PHQ-9, GAD-7, SBQ-R, and DERS-SF, over all conditions, controlling for condition, for a condition x app use interaction, and for condition x time."

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended
18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory analyses.

Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not applicable to this study.

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

subitem not at all important 〇 〇 〇 〇 〇 essential
Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is not applicable to this study.

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harms or unintended effects reported.

19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical “harm” to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. “Unintended effects” also includes unintended positive effects [2].

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | ○ | ○ | ○ | ○ | ○ | essential |
Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No privacy breaches or technical problems occurred.

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Only quantitative feedback on usability, acceptability, and appropriateness was obtained.

DISCUSSION
22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |

Does your paper address subitem 22-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is done. For example, "Our primary findings are that commercial mobile mental health apps are found to be usable, acceptable and had a positive impact on depression and anxiety, but not emotional regulation or suicide risk.:

22-ii) Highlight unanswered new questions, suggest future research
Highlight unanswered new questions, suggest future research.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |
Does your paper address subitem 22-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

This is done. For example, "Understanding the risks of using commercial apps is as important as determining their impacts and should be explored in future studies."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |   |   |   |   |
| essential                    |   |   |   |   |

Does your paper address subitem 20-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is done. For example, "Study limitations include the following: (1) our sample consisted of participants from Prolific, and thus may be most representative of essential workers or COVID-19 unemployed persons who are proactively seeking other sources of income to offset financial stress......(2) because we did not partner with the technology companies who created the study apps, we relied on self-reported app use, which may be subject to self-report bias......(3) While we justify our timeline for measuring outcomes after 4 weeks of intervention use based on what is typical for most mental health app users, we do not have information on the lasting effects of treatment outcome or on continued app use.....(4) we did not ask about potential adverse events related to app use. This is an interesting area of research that to date has not been explored. Understanding the risks of using commercial apps is as important as determining their impacts and should be explored in future studies."

21) Generalisability (external validity, applicability) of the trial findings
NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations
Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

| subitem not at all important | 1 | 2 | 3 | 4 | 5 | essential |
|-----------------------------|---|---|---|---|---|-----------|
|                             |   |   |   |   |   | essential |
Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

This is described in the study strengths and conclusion sections.

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

Subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Not applicable to this study.

OTHER INFORMATION

23) Registration number and name of trial registry
Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes: "Trial Registration: Mobile Mental Health Apps for Suicide Prevention, NCT04536935, https://clinicaltrials.gov/ct2/show/NCT04536935"

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Trial Registration: Mobile Mental Health Apps for Suicide Prevention, NCT04536935, https://clinicaltrials.gov/ct2/show/NCT04536935"

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Funding: This study was supported by the National Institute of Mental Health (P50MH115837). The funding body has no role in study design, writing of the manuscript, or decision to submit the article for publication."
X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem X27-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

○ yes, major changes
○ yes, minor changes
○ no
What were the most important changes you made as a result of using this checklist?

We added increased detail about the web-based assessment protocols.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript

Twelve hours spent on the checklist and related changes to the manuscript

As a result of using this checklist, do you think your manuscript has improved? *

- yes
- no
- Other:

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- Other:

Clear selection
Any other comments or questions on CONSORT EHEALTH

Your answer

STOP - Save this form as PDF before you click submit
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!
Click submit so we have your answers in our database!